Novartis (NVS) has discontinued the development of VHB937/lifonebart, an experimental therapy for a fatal nervous system disease known as amyotrophic lateral sclerosis, following a mid-stage trial ...
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...
Novartis AG halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig’s ...
Axoltis Pharma announced today that its phase 2 trial for amyotrophic lateral sclerosis (ALS) has missed its primary endpoint ...
Novartis AG (NYSE: NVS) has discontinued development of an experimental drug for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease, after a mid-stage clinical trial failed ...
Filmmaker and University of Virginia graduate Chris Farina had the idea for a documentary about death and dying about 10 ...
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env ...
A new study published in Scientific Reports indicates that amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have an extremely high geographic association, even after controlling for ...
A German population-based registry study identifies survival patterns and predictors of longer survival in patients with ...
In people with amyotrophic lateral sclerosis (ALS), changes in neurons appear to activate immune cells. Lowering the inflammation could reduce the symptoms of the disease, according to a study led by ...
Every 90 minutes, someone is diagnosed with amyotrophic lateral sclerosis (ALS), often called Lou Gehrig’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results